<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230117057153N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-01</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of midazolam in oral and nebulized form</public_title>
      <acronym></acronym>
      <scientific_title>Assessment and Comparison of the effectiveness of nebulized vs. oral midazolam as a sedative premedication in pediatric eye surgery patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68081</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: A randomization list will be generated using a table with the random property in Excel. After that, the information will be sent in numbered sealed envelopes, Blinding description: The person assessing the outcomes of the information will be unaware of the drug given to each patients.</study_design>
      <phase>2-3</phase>
      <hc_freetext>This study is conducted for sedation in children undergoing eye surgeries. The entry criteria of our children should not have any underlying disease and be between 3 and 7 years old..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  The patients will receive the nebulized midazolam will be 0.5 mg/kg in 5  cc normal saline and will be nebulized through the face mask. Intervention 2: Patients will recieve oral solution which is 0.5 mg/kg (the standard midazolam syrup) and the face mask used for them will not contain any form of drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further explanation.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sumaiya Zahra</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dormitory Kuye Daneshgar, Amirabad, North Kargar St., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1439957181</zip>
        <telephone>+98 21 8800 2651</telephone>
        <email>sumaiyazahra110@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sumaiya Zahra</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kuye Daneshgah, North Karegar, Amirabad, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1439957181</zip>
        <telephone>+98 21 8889 6692</telephone>
        <email>sumaiyazahra25998@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>ASA I and II
Children aged 3 to 7 years
Eye surgery under general anesthesia</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>7 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with renal or hepatic dysfunction
History of midazolam allergy
History of asthma
Pre-existing neurologic disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  The patients will receive the nebulized midazolam will be 0.5 mg/kg in 5  cc normal saline and will be nebulized through the face mask.</i_keyword>
      <i_keyword>Patients will recieve oral solution which is 0.5 mg/kg (the standard midazolam syrup) and the face mask used for them will not contain any form of drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determining sedation level using RAMSAY score within 30 minutes after administration of nebulized vs oral midazolam in pediatric eye surgery patients. Timepoint: 30 minutes after drug administration. Method of measurement: RAMSAY sedation score (0-6).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Time taken to reach RSS 4 (RSS= Ramsay Sedation Score ). Timepoint: Within 30 minutes whenever it reaches RSS 4. Method of measurement: Time Unit.</sec_outcome>
      <sec_outcome>Facemask acceptance during drug delivery. Timepoint: During the sedation procedure. Method of measurement: Four point Mask Acceptance Scale                                                        1.Excellent: Unafraid, cooperative, and accepts mask easily. 2, Good: Slight fear of mask, easily reassurediii. 3. Fair: Moderate fear of mask, not calmed with reassuranceiv. 4. Poor: Terrified, crying and combative.</sec_outcome>
      <sec_outcome>Ease of separation from parents. Timepoint: At the end of drug delivery (after 30 minute). Method of measurement: Parental Separation Anxiety Scale (PSAS)                                            Excellent = Patient unafraid, cooperative, or asleep                                Good= Slightly afraid/crying, quiet with reassurance                              Fair= Moderately afraid and crying, not quiet with reassurance                 Poor= Crying, need for restraint.</sec_outcome>
      <sec_outcome>Changes in oxygen saturation. Timepoint: Baseline (at 0 minute after nebulization), 15th miinute and at 30th minute. Method of measurement: Oxygen saturation by pulse oximetry.</sec_outcome>
      <sec_outcome>Changes in heart rate. Timepoint: At 0 minute after nebulization, 15th minute and 30th minute. Method of measurement: Heart rate in beat/minute.</sec_outcome>
      <sec_outcome>Changes in blood pressure. Timepoint: At 0 minute after nebulization, 15th minute and 30th minute. Method of measurement: Blood pressure in mmHg.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-12</approval_date>
        <contact_name>Ethics comittee of Tehran University of Medical Sciences</contact_name>
        <contact_address>13th Floor, Block- A, Central Headquarters of the Ministry of Health and Medical Education, Iran Sima Street, Quds Town (West), between South Flamek and Zarafshan, Quds Town (West), Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
